

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
23 June 2005 (23.06.2005)

PCT

(10) International Publication Number  
WO 2005/056595 A2

(51) International Patent Classification<sup>7</sup>: C07K 14/705

(21) International Application Number:  
PCT/GB2004/005100

(22) International Filing Date: 6 December 2004 (06.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0328363.7 6 December 2003 (06.12.2003) GB

(71) Applicant (for all designated States except US): IM-  
PERIAL COLLEGE INNOVATIONS LIMITED  
[GB/GB]; Sherfield Building, Imperial College, London  
SW7 2AZ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): STAUSS, Hans,  
Josef [DE/GB]; Department of Immunology, Ham-  
mersmith Hospital Campus, Imperial College London, Du  
Cane Road, London W12 0NN (GB). GAO, Liqueun  
[GB/GB]; Dept. of Immunology, Hammersmith Hospital

Campus, Imperial College London, Du Cane Road, Lon-  
don W12 0NN (GB). XUE, Shao-An [CN/GB]; Dept. of  
Immunology, Hammersmith Hospital Campus, Imperial  
College London, Du Cane Road, London W12 0NN (GB).

(74) Agent: MILES, John; Eric Potter Clarkson, Park View  
House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

[Continued on next page]

(54) Title: THERAPEUTICALLY USEFUL MOLECULES

## Human TCR V $\alpha$ -1.5 (V $\alpha$ -8.2) coding sequence

```
ATGCTCCTGC TGCTCGTCCC AGTGCTCGAG GTGATTTTCTA CTCTGGGAGG
AACCAGAGCC CAGTCGGTGA CCCAGCTTGA CAGCCACGTC TCTGTCTCTG
AAGGAACCCC GGTGCTGCTG AGGTGCAACT ACTCATCTTC TTATTCACCA
TCTCTCTTCT GGTATGTGCA ACACCCCAAC AAAGGACTCC AGCTTCTCCT
GAAGTACACA TCAGCGGCCA CCTTGTTTAA AGGCATCAAC GGTTTTGAGG
CTGAATTTAA GAAGAGTGAA ACCTCCTTCC ACCTGACGAA ACCCTCAGCC
CATATGAGCG ACGCGGCTGA GTACTTCTGT GTTGTGAGTC CTTTTTCAGG
AGGAGGTGCT GACGGACTCA CCTTTGGCAA AGGGACTCAT CTAATCATCC
AGCCCTATAT CCAGAACCCT GACCCTGCCG TGTACCAGCT GAGAGACTCT
AAATCCAGTG ACAAGTCTGT CTGCCTATTG ACCGATTTTG ATTCTCAAAC
AAATGTGTCA CAAAGTAAGG ATTCTGATGT GTATATCACA GACAAAACCTG
TGCTAGACAT GAGGTCTATG GACTTCAAGA GCAACAGTGC TGTGGCCTGG
AGCAACAAAT CTGACTTTGC ATGTGCAAAC GCCTTCAACA ACAGCATTAT
TCCAGAAGAC ACCTTCTTCC CCAGCCGAGA AAGTTCCTGT GATGTCAAGC
TGGTCGAGAA AAGCTTTGAA ACAGATACGA ACCTAAACTT TCAAACCTG
TCAGTGATTG GGTTCGGAAT CCTCCTCCTG AAAGTGGCCG GGTTTAACTC
GCTCATGACG CTGCGGCTGT GGTCCAGCTG A
```

(57) Abstract: A T cell receptor molecule (TCR) containing an alpha chain portion and a beta chain portion wherein the alpha chain portion contains three complementarity determining regions (CDRs): CDR1 $\alpha$ : SSYSPS CDR2 $\alpha$ : YTSAAITL CDR3 $\alpha$ : VVSPF-SGGGADGLT or comprising or consisting of SPFSGGGADGLT and the beta chain portion contains three complementarity determining regions (CDRs): CDR1 $\beta$ : DFQATT CDR2 $\beta$ : SNEGSKA CDR3 $\beta$ : comprising SARDGGEG or comprising or consisting of RDGGEGSETQY, or wherein up to three amino acid residues in one or more CDRs are replaced by another amino acid residue. The invention also includes polynucleotides encoding the TCR molecules, and host cells containing the said polynucleotides. Patient derived T cells may have the polynucleotides encoding the TCR molecules introduced therein, and the engineered T cells may be introduced into the patient in order to combat a WT1-expressing malignancy.

WO 2005/056595 A2



SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*